Trial · NCT06946849
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
NCT06946849, Phase 2, Not yet recruiting, Shanghai Zhongshan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study. Trials, record NCT06946849. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06946849
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
- NCT number
- NCT06946849
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 76 participants, estimated
- Lead sponsor
- Shanghai Zhongshan Hospital
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)
- Interventions
- radiotherapy, FOLFIRI or FOLFOX or Regorafenib
- First posted
- 2025-04-27
- Last updated
- 2025-04-27
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS | Up to 2 years | PFS is will be measured from the randomization to progression or death from any cause. Progression includes enlargement of target lesions and development of new distant metastases and will be assessed using RECIST 1.1. |
| Secondary | OS | Up to 2 years | OS will be the time from randomization until death from any cause. |
| Secondary | LCR | Up to 2 years | Local control of all metastases (refers to all lesions present at time of randomization) will be measured from date of randomization until progression of target lesions. |
| Secondary | AEs | Up to 2 years | Toxicity will involve treatment-related toxicity, including early and late toxicity, as assessed using Common Terminology Criteria for Adverse Events v5.0. All adverse events occurring from randomization until 3 months after the end of treatment, regardless of relatedness to study medication, will be recorded as acute toxicities. Adverse events considered relevant and occurring later than 3 months after the end of treatment will be recorded as late toxicities. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06946849
GET https://conductscience.org/api/trials/v1/NCT06946849/registered